Your browser doesn't support javascript.
loading
Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma.
Pölönen, Petri; Jawahar Deen, Ashik; Leinonen, Hanna M; Jyrkkänen, Henna-Kaisa; Kuosmanen, Suvi; Mononen, Mimmi; Jain, Ashish; Tuomainen, Tomi; Pasonen-Seppänen, Sanna; Hartikainen, Jaana M; Mannermaa, Arto; Nykter, Matti; Tavi, Pasi; Johansen, Terje; Heinäniemi, Merja; Levonen, Anna-Liisa.
Afiliación
  • Pölönen P; Institute of Biomedicine, School of Medicine, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Jawahar Deen A; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Leinonen HM; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Jyrkkänen HK; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Kuosmanen S; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Mononen M; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Jain A; Institute of Medical Biology, University of Tromsø, 9037, Tromsø, Norway.
  • Tuomainen T; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, N-0379, Oslo, Norway.
  • Pasonen-Seppänen S; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, P. O. Box 1627, N-0379, Oslo, Norway.
  • Hartikainen JM; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Mannermaa A; Institute of Biomedicine, School of Medicine, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Nykter M; Institute of Clinical Medicine, University of Eastern Finland, P. O. Box 1627, FIN-70211, Kuopio, Finland.
  • Tavi P; Institute of Clinical Medicine, University of Eastern Finland, P. O. Box 1627, FIN-70211, Kuopio, Finland.
  • Johansen T; Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, P. O. Box 100, FIN-33014, Tampere, Finland.
  • Heinäniemi M; Institute of Biomedicine, School of Medicine, University of Eastern Finland, P.O. Box 1627, FIN-70211, Kuopio, Finland.
  • Levonen AL; Institute of Medical Biology, University of Tromsø, 9037, Tromsø, Norway.
Oncogene ; 38(50): 7473-7490, 2019 12.
Article en En | MEDLINE | ID: mdl-31444413
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Glioblastoma / Factor 2 Relacionado con NF-E2 / Proteína 1 Asociada A ECH Tipo Kelch / Proteína Sequestosoma-1 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Finlandia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Glioblastoma / Factor 2 Relacionado con NF-E2 / Proteína 1 Asociada A ECH Tipo Kelch / Proteína Sequestosoma-1 Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Oncogene Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Finlandia